<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00314561</url>
  </required_header>
  <id_info>
    <org_study_id>KoreaUAnanmH</org_study_id>
    <nct_id>NCT00314561</nct_id>
  </id_info>
  <brief_title>The Effect of Pioglitazone and Rosiglitazone on Atherosclerotic and Inflammatory Markers in Patients With Metabolic Syndrome</brief_title>
  <official_title>The Effect of Pioglitazone and Rosiglitazone on Atherosclerotic and Inflammatory Markers in Patients With Metabolic Syndrome: A Prospective, Randomized, Open-label, Crossover Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea University Anam Hospital</source>
  <brief_summary>
    <textblock>
      Pioglitazone and rosiglitazone are used in the treatment of diabetic patients.
      Thiazolidinediones increase insulin sensitivity and show favorable effect blood glucose
      levels and lipid profiles. The effect of these two different thiazolidinediones on
      atherosclerotic and inflammatory markers has not been compared in prospective manner. The
      purpose of this prospective, randomized, open-label, crossover trial is to compare the effect
      of pioglitazone and rosiglitazone on atherosclerotic and inflammatory markers in patients
      with metabolic syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date>December 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effect on flow-mediated dilation (FMD) and pulse wave velocity (PWV)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The effect of atherosclerotic and inflammatory markers such as adiponectin, IL-6, TNF-α, hsCRP.</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>Metabolic Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone, Rosiglitazone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with at least 3 metabolic syndrome criteria of Asian-Pacific ATP III
             guideline: fasting blood glucose ≥ 110 mg/dl, systolic blood pressure ≥ 130 mmHg or
             diastolic blood pressure ≥ 85 mmHg, triglyceride ≥ 150 mg/dl, HDL-cholesterol &lt; 40
             mg/dl for men and &lt; 50 mg/dl for women.

          -  Age: 18 years and above

        Exclusion Criteria:

          -  Hypertensive patients with the use of ACE inhibitor or ARB

          -  Hyperlipidemic patients with the use of statin or fenofibrate

          -  Patients with any contraindications to the treatment of thiazolidinediones

          -  Pregnant or lactating patients

          -  Chronic alcohol or drug abuse

          -  Hepatic dysfunction

          -  Renal dysfunction

          -  Heart failure (EF &lt; 50%)

          -  Expected life expectancy of &lt; 1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong Sup Choi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2006</study_first_submitted>
  <study_first_submitted_qc>April 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2006</study_first_posted>
  <last_update_submitted>June 30, 2011</last_update_submitted>
  <last_update_submitted_qc>June 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2011</last_update_posted>
  <keyword>Rosiglitazone</keyword>
  <keyword>Pioglitazone</keyword>
  <keyword>FMD</keyword>
  <keyword>PWV</keyword>
  <keyword>atherosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Rosiglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

